Point-of-Care Molecular Diagnostics Market In-deep Analysis and Healthcare Experts Review Report Outlook - 2026 (Based on 2020 COVID-19 Worldwide Spread)

Latest Industry Research Report On global Point-of-Care Molecular Diagnostics Market Research Report 2020 in-depth analysis of the market state and also the competitive landscape globally.

The Point-of-Care Molecular Diagnostics market report provides information regarding market size, share, trends, growth, cost structure, global market competition landscape, market drivers, challenges and opportunity, capacity, revenue and forecast 2026. This report also includes the overall and comprehensive study of the Point-of-Care Molecular Diagnostics market with all its aspects influencing the growth of the market. This report is exhaustive quantitative analyses of the Point-of-Care Molecular Diagnostics industry and provides data for making strategies to increase market growth and effectiveness.

This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Click the link to get a Sample Copy of the Report before purchase:

https://www.marketinsightsreports.com/reports/07041342397/global-point-of-care-molecular-diagnostics-market-size-status-and-forecast-2019-2025/inquiry?Mode=56&Source=openpr

The Following Top Key Players in the Point-of-Care Molecular Diagnostics Market:

Abbott Laboratories
Bayer Healthcare
Hoffmann-La Roche AG
Becton
Dickinson and Company
BioMerieux
Bio-Rad Laboratories, Inc.
Cepheid, Inc.
Danaher Corporation
Johnson and Johnson, and other.

Industry News:

Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes

ABBOTT PARK, Ill., March 27, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes. The test will run on the company's ID NOW(TM) platform, providing rapid results in a wide range of healthcare settings such as physicians' offices, urgent care clinics and hospital emergency departments.

The ID NOW platform is small, lightweight (6.6 pounds) and portable (the size of a small toaster), and uses molecular technology, which is valued by clinicians and the scientific community for its high degree of accuracy. ID NOW is already the most widely available molecular point-of-care testing platform in the U.S. today.

"The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus," said Robert B. Ford, president and chief operating officer, Abbott. "With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots."

Abbott will be making ID NOW COVID-19 tests available next week to healthcare providers in urgent care settings in the U.S., where the majority of ID NOW instruments are in use today. The company is working with the Administration to deploy tests to areas where they can have the greatest impact.

This report segments the Point-of-Care Molecular Diagnostics market on the basis of Types are:

PCR-based
Genetic Sequencing-based
Hybridization-based
Microarray-based
Other

On the basis of Application, the Point-of-Care Molecular Diagnostics market is segmented into:

Infectious Diseases
Oncology
Hematology
Prenatal Testing
Endocrinology
Other

Inquiry for discount (Exclusive offer: get flat 20% discount):

https://www.marketinsightsreports.com/reports/07041342397/global-point-of-care-molecular-diagnostics-market-size-status-and-forecast-2019-2025/discount?Mode=56&Source=openpr

Regional outlook: The regions covered in the reports of the Point-of-Care Molecular Diagnostics market are

North America (United States, Canada, and Mexico)
Asia-Pacific (China, India, Japan, South Korea, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam)
Europe (Germany, France, UK, Italy, Russia, Rest of Europe)
Central & South America (Brazil, Rest of South America)
Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Other)

Highlights the following key factors:

- Business description: - A detailed description of the company's operations and business divisions.
- Corporate strategy: - Analyst's summarization of the company's business strategy.
- SWOT Analysis: - A detailed analysis of the company's strengths, weaknesses, opportunities, and threats.
- Company history: - Progression of key events associated with the company.
- Major products and services: - A list of major products, services, and brands of the company.
- Key competitors: - A list of key competitors to the company.
- Important locations and subsidiaries: - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years: - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

The report has 150 tables and figures browse the report description and TOC:

https://www.marketinsightsreports.com/reports/07041342397/global-point-of-care-molecular-diagnostics-market-size-status-and-forecast-2019-2025?Mode=56&Source=openpr

We also offer customization on reports based on specific client requirement:

- Free country-level analysis for any 5 countries of your choice.
- Free Competitive analysis of any 5 key market players.
- Free 40 analyst hours to cover any other data points.

Scope of the report:

The report evaluates the growth rate and the Market value based on Market dynamics, growth inducing factors. The complete knowledge is based on the latest industry news, opportunities and trends. The report contains a comprehensive Market analysis and vendor landscape in addition to a SWOT analysis of the key vendors.

Note - All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

You Can Browse Following Related Reports

COVID-19 Impact On Point-of-Care Infectious Disease Diagnostics/Testing Market, Global Research Reports 2020-2021
https://www.marketinsightsreports.com/reports/05242042234/covid-19-impact-on-point-of-care-infectious-disease-diagnostics-testing-market-global-research-reports-2020-2021?Mode=56

Global Point-of-Care Testing Market Report 2020 By Key Players, Types, Applications, Countries, Market Size, Forecast To 2026 (Based On 2020 COVID-19 Worldwide Spread)
https://www.marketinsightsreports.com/reports/05282051803/global-point-of-care-testing-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?Mode=56

COVID-19 Impact On Point Of Care Diagnostic Devices Market, Global Research Reports 2020-2021
https://www.marketinsightsreports.com/reports/05282050576/covid-19-impact-on-point-of-care-diagnostic-devices-market-global-research-reports-2020-2021?Mode=56

Contact Us:
Irfan Tamboli (Head of Sales) Market Insights Reports
sales@marketinsightsreports.com | irfan@marketinsightsreports.com
Phone: - + 1704 266 3234 | +91-750-707-8687

About Us:
MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.